New positive results from GSK’s TB vaccine in HIV negative patients

GSK announce promising results from a study conducted in partnership with non-profit scientific research organisation IAVI, that is investigating the efficacy of the company’s tuberculosis (TB) vaccine in HIV-negative adults with latent TB infection. The study was conducted across 11 sites throughout Kenya, South Africa and Zambia, which are all TB-endemic regions, and enrolled over

Continue Reading

1,500 GSK Contractors written to by HMRC in reference to “disguised employment”

IR35 rules are designed to stop tax avoidance by workers who provide services to clients via a limited company rather than as employees.  A contractor operating through a Limited company but otherwise practically operating as an employee is considered to be a “disguised employee”. HMRC stated there is evidence that contractors in the pharmaceutical industry

Continue Reading

UK Government & Pharma Invest £52 Million to Improve UK Science Skills

David Willetts, the UK’s Science Minister, yesterday announced an investment of £52 million for the UK’s science sectors to improve skills and vocational training. The announcement was made at the official launch of the Science and Industrial Partnership (SIP), which is being led by GlaxoSmithKline (GSK). The announcement is expected to create over ‘7,800 education

Continue Reading

European Medicines Agency Approves GSK / Theravance’s Relvar

GlaxoSmithKline (GSK) and Theravance’s inhaled lung drug, Relvar, has been approved by Europe’s regulatory body to treat both asthma and chronic obstructive pulmonary disease (COPD). Relvar is a combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2 agonist (LABA) vilanterol, and is delivered through the Ellipta inhaler.  The drug has already been approved

Continue Reading

Relvar Ellipta Supported by EMA Advisors

Advisors to the European Medicines Agency (EMA) have voted in support of approving GlaxoSmithKline/ Theravance’s Relvar Ellipta for both asthma and chronic obstructive pulmonary disease (COPD). The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has delivered a response recommending marketing authorisation for Relvar Ellipta, a combination of the inhaled corticosteroid fluticasone

Continue Reading